Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 83. More products

ESTRADIOL

Form:

7 of 7 products shown

4 general benefit · 3 not a benefit

Other products in the same Health Canada class (G03CA) — coverage varies; not interchangeable

  • Conjugated estrogens (Premarin): general benefit, Limited Use 398

Lupin-Estradiol · DIN 02449048 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lupin-Estradiol · DIN 02449048 Manufacturer: Lupin Pharma Canada Limited; listing date 2016-04-29 Health Canada: Marketed since 2016-02-29 · brand LUPIN-ESTRADIOL · ATC G03CA03 ESTRADIOL · form Tablet · route Oral · ingredients ESTRADIOL (ESTRADIOL HEMIHYDRATE) 0.5 MG · company Lupin pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Lupin-Estradiol: Formulary list price $0.1199/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1199 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93486 · Verify on the e-Formulary ↗ (DIN 02449048)

Source record
DIN 02449048: Lupin-Estradiol Raw flags: sec3=Y Item: 681600051; group id 733; item number 1797; lccId None; manufacturer id LUP Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $0.1199; ministry $0.1199 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449048 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93486
Interchangeable products
Estrace · DIN 02225190 · not recorded
Shortage status: resolved shortage (ended 2026-06-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449048
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupin-Estradiol · DIN 02449056 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lupin-Estradiol · DIN 02449056 Manufacturer: Lupin Pharma Canada Limited; listing date 2016-04-29 Health Canada: Marketed since 2016-02-29 · brand LUPIN-ESTRADIOL · ATC G03CA03 ESTRADIOL · form Tablet · route Oral · ingredients ESTRADIOL (ESTRADIOL HEMIHYDRATE) 1 MG · company Lupin pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Lupin-Estradiol: Formulary list price $0.2313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93487 · Verify on the e-Formulary ↗ (DIN 02449056)

Source record
DIN 02449056: Lupin-Estradiol Raw flags: sec3=Y Item: 681600036; group id 733; item number 1798; lccId None; manufacturer id LUP Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.2313; ministry $0.2313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449056 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93487
Interchangeable products
Estrace · DIN 02148587 · not recorded
Shortage status: resolved shortage (ended 2026-09-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449056
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupin-Estradiol · DIN 02449064 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lupin-Estradiol · DIN 02449064 Manufacturer: Lupin Pharma Canada Limited; listing date 2016-04-29 Health Canada: Marketed since 2016-02-29 · brand LUPIN-ESTRADIOL · ATC G03CA03 ESTRADIOL · form Tablet · route Oral · ingredients ESTRADIOL (ESTRADIOL HEMIHYDRATE) 2 MG · company Lupin pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Lupin-Estradiol: Formulary list price $0.4083/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4083 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93488 · Verify on the e-Formulary ↗ (DIN 02449064)

Source record
DIN 02449064: Lupin-Estradiol Raw flags: sec3=Y Item: 681600037; group id 733; item number 1799; lccId None; manufacturer id LUP Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.4083; ministry $0.4083 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449064 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93488
Interchangeable products
Estrace · DIN 02148595 · not recorded
Shortage status: resolved shortage (ended 2026-09-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449064
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Estring · DIN 02168898 · 2mg · Vag Ring

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Estring · DIN 02168898 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-04-13 · brand ESTRING · ATC G03CA03 ESTRADIOL · form Ring (slow-release) · route Vaginal · ingredients ESTRADIOL 2 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Estring: Formulary list price $106.5400/unit (unit not stated in source; not the patient's cost)

Ministry pays: $106.5400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18640 · Verify on the e-Formulary ↗ (DIN 02168898)

Source record
DIN 02168898: Estring Raw flags: sec3=Y Item: 681600041; group id 733; item number 1800; lccId None; manufacturer id PFI Source form: Vag Ring; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $106.5400; ministry $106.5400 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02168898 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18640
Shortage status: resolved shortage (ended 2025-04-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02168898
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Estrace · DIN 02225190 · 0.5mg · tablet

Listed, not a benefitDormant since 2023-12-15 · checked 2026-09-02 · What does dormant mean?
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Estrace · DIN 02225190 Manufacturer: Acerus Pharmaceuticals Corporation; listing date 2016-04-29 Health Canada: Dormant since 2023-12-15 · brand PMS-ESTRADIOL · ATC G03CA03 ESTRADIOL · form Tablet · route Oral · ingredients ESTRADIOL 0.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Estrace: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43420 · Verify on the e-Formulary ↗ (DIN 02225190)

Source record
DIN 02225190: Estrace Raw flags: notABenefit=Y, sec3=Y Item: 681600051; group id 733; item number 1797; lccId None; manufacturer id APC Source form: Tab; strength: 0.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02225190 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43420
Interchangeable products
Lupin-Estradiol · DIN 02449048 · $0.1199
Shortage status: active shortage (reported 2019-07-01, last updated 2021-10-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02225190
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2023-12-15 — choose a marketed DIN from the same-category list.

Estrace · DIN 02148587 · 1mg · tablet

Listed, not a benefitDormant since 2023-12-15 · checked 2026-09-02
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Estrace · DIN 02148587 Manufacturer: Acerus Pharmaceuticals Corporation; listing date 2016-04-29 Health Canada: Dormant since 2023-12-15 · brand PMS-ESTRADIOL · ATC G03CA03 ESTRADIOL · form Tablet · route Oral · ingredients ESTRADIOL 1 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Estrace: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19406 · Verify on the e-Formulary ↗ (DIN 02148587)

Source record
DIN 02148587: Estrace Raw flags: notABenefit=Y, sec3=Y Item: 681600036; group id 733; item number 1798; lccId None; manufacturer id APC Source form: Tab; strength: 1mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02148587 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19406
Interchangeable products
Lupin-Estradiol · DIN 02449056 · $0.2313
Shortage status: active shortage (reported 2019-07-01, last updated 2021-10-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02148587
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2023-12-15 — choose a marketed DIN from the same-category list.

Estrace · DIN 02148595 · 2mg · tablet

Listed, not a benefitDormant since 2023-12-15 · checked 2026-09-02
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Estrace · DIN 02148595 Manufacturer: Acerus Pharmaceuticals Corporation; listing date 2016-04-29 Health Canada: Dormant since 2023-12-15 · brand PMS-ESTRADIOL · ATC G03CA03 ESTRADIOL · form Tablet · route Oral · ingredients ESTRADIOL 2 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Estrace: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19405 · Verify on the e-Formulary ↗ (DIN 02148595)

Source record
DIN 02148595: Estrace Raw flags: notABenefit=Y, sec3=Y Item: 681600037; group id 733; item number 1799; lccId None; manufacturer id APC Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02148595 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19405
Interchangeable products
Lupin-Estradiol · DIN 02449064 · $0.4083
Shortage status: active shortage (reported 2019-07-01, last updated 2021-10-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02148595
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2023-12-15 — choose a marketed DIN from the same-category list.

ESTRADIOL HEMIHYDRATE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (G03CA) — coverage varies; not interchangeable

  • Conjugated estrogens (Premarin): general benefit, Limited Use 398

Imvexxy · DIN 02503689 · 4mcg · Vag Insert

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Imvexxy · DIN 02503689 Manufacturer: Knight Therapeutics Inc.; listing date 2023-11-30 Health Canada: Marketed since 2023-11-14 · brand IMVEXXY · ATC G03CA03 ESTRADIOL · form Insert · route Vaginal · ingredients ESTRADIOL (ESTRADIOL HEMIHYDRATE) 4 MCG/INSERT · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Imvexxy: Formulary list price $3.6942/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.6942 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99313 · Verify on the e-Formulary ↗ (DIN 02503689)

Source record
DIN 02503689: Imvexxy Raw flags: sec3=Y Item: 681600079; group id 735; item number 1802; lccId None; manufacturer id KNT Source form: Vag Insert; strength: 4mcg Recorded listing: General benefit Source prices (unrounded): $3.6942; ministry $3.6942 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02503689 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99313
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02503689
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Imvexxy · DIN 02503697 · 10mcg · Vag Insert

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Imvexxy · DIN 02503697 Manufacturer: Knight Therapeutics Inc.; listing date 2023-11-30 Health Canada: Marketed since 2023-11-14 · brand IMVEXXY · ATC G03CA03 ESTRADIOL · form Insert · route Vaginal · ingredients ESTRADIOL (ESTRADIOL HEMIHYDRATE) 10 MCG/INSERT · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Imvexxy: Formulary list price $3.6942/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.6942 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99314 · Verify on the e-Formulary ↗ (DIN 02503697)

Source record
DIN 02503697: Imvexxy Raw flags: sec3=Y Item: 681600080; group id 735; item number 1803; lccId None; manufacturer id KNT Source form: Vag Insert; strength: 10mcg Recorded listing: General benefit Source prices (unrounded): $3.6942; ministry $3.6942 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02503697 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99314
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02503697
Shortage record checked 2026-09-13T08:10:21.292534+00:00

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (G03CA) — coverage varies; not interchangeable

  • Conjugated estrogens (Premarin): general benefit, Limited Use 398

AMB-Cyproterone Acetate/EthinylEstradiol · DIN 02564424 · 2mg & 0.035mg · tablets, 21-pack

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
AMB-Cyproterone Acetate/EthinylEstradiol · DIN 02564424 Manufacturer: Ambicare Pharmaceuticals Inc.; listing date 2026-05-29 Health Canada: Marketed since 2026-03-19 · brand AMB-CYPROTERONE ACETATE / ETHINYL ESTRADIOL · ATC G03HB01 CYPROTERONE AND ESTROGEN · form Tablet · route Oral · ingredients CYPROTERONE ACETATE 2 MG, ETHINYL ESTRADIOL 0.035 MG · company Ambicare pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106712 · Verify on the e-Formulary ↗ (DIN 02564424)

Source record
DIN 02564424: AMB-Cyproterone Acetate/EthinylEstradiol Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 683200100; group id 792; item number 1929; lccId None; manufacturer id AMB Source form: Tab-21 Pk; strength: 2mg & 0.035mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $23.3394; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02564424 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106712
Interchangeable products
Cleo-35 · DIN 02436736 · not recorded Cyestra-35 · DIN 02290308 · not recorded Diane-35 · DIN 02233542 · not recorded Ran-Cyproterone/Ethinyl Estradiol · DIN 02425017 · not recorded Teva-Cyproterone/Ethinyl Estradiol · DIN 02309556 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02564424
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cleo-35 · DIN 02436736 · 2mg & 0.035mg · tablets, 21-pack

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Cleo-35 · DIN 02436736 Manufacturer: Altius Healthcare Inc.; listing date 2024-10-31 Health Canada: Marketed since 2018-05-04 · brand CLÉO -35 · ATC G03HB01 CYPROTERONE AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.035 MG, CYPROTERONE ACETATE 2 MG · company Altius healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92104 · Verify on the e-Formulary ↗ (DIN 02436736)

Source record
DIN 02436736: Cleo-35 Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 683200100; group id 792; item number 1929; lccId None; manufacturer id ALH Source form: Tab-21 Pk; strength: 2mg & 0.035mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $23.3394; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02436736 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92104
Interchangeable products
AMB-Cyproterone Acetate/EthinylEstradiol · DIN 02564424 · not recorded Cyestra-35 · DIN 02290308 · not recorded Diane-35 · DIN 02233542 · not recorded Ran-Cyproterone/Ethinyl Estradiol · DIN 02425017 · not recorded Teva-Cyproterone/Ethinyl Estradiol · DIN 02309556 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02436736
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cyestra-35 · DIN 02290308 · 2mg & 0.035mg · tablets, 21-pack

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Cyestra-35 · DIN 02290308 Manufacturer: Paladin Labs Inc.; listing date 2007-12-19 Health Canada: Marketed since 2026-02-17 · brand CYESTRA-35 · ATC G03HB01 CYPROTERONE AND ESTROGEN · form Tablet · route Oral · ingredients CYPROTERONE ACETATE 2 MG, ETHINYL ESTRADIOL 0.035 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77558 · Verify on the e-Formulary ↗ (DIN 02290308)

Source record
DIN 02290308: Cyestra-35 Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 683200100; group id 792; item number 1929; lccId None; manufacturer id PAL Source form: Tab-21 Pk; strength: 2mg & 0.035mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $23.3394; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02290308 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77558
Interchangeable products
AMB-Cyproterone Acetate/EthinylEstradiol · DIN 02564424 · not recorded Cleo-35 · DIN 02436736 · not recorded Diane-35 · DIN 02233542 · not recorded Ran-Cyproterone/Ethinyl Estradiol · DIN 02425017 · not recorded Teva-Cyproterone/Ethinyl Estradiol · DIN 02309556 · not recorded
Shortage status: resolved shortage (ended 2026-03-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02290308
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diane-35 · DIN 02233542 · 2mg & 0.035mg · tablets, 21-pack

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Diane-35 · DIN 02233542 Manufacturer: Bayer Inc., Consumer Care Division; listing date 2007-12-19 Health Canada: Marketed since 2007-12-17 · brand DIANE-35 · ATC G03HB01 CYPROTERONE AND ESTROGEN · form Tablet · route Oral · ingredients CYPROTERONE ACETATE 2 MG, ETHINYL ESTRADIOL 35 MCG · company Bayer inc · schedule Prescription
Check this DIN again · Health Canada product record

Diane-35: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=53444 · Verify on the e-Formulary ↗ (DIN 02233542)

Source record
DIN 02233542: Diane-35 Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 683200100; group id 792; item number 1929; lccId None; manufacturer id BAY Source form: Tab-21 Pk; strength: 2mg & 0.035mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02233542 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=53444
Interchangeable products
AMB-Cyproterone Acetate/EthinylEstradiol · DIN 02564424 · not recorded Cleo-35 · DIN 02436736 · not recorded Cyestra-35 · DIN 02290308 · not recorded Ran-Cyproterone/Ethinyl Estradiol · DIN 02425017 · not recorded Teva-Cyproterone/Ethinyl Estradiol · DIN 02309556 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02233542
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Cyproterone/Ethinyl Estradiol · DIN 02425017 · 2mg & 0.035mg · tablets, 21-pack

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Cyproterone/Ethinyl Estradiol · DIN 02425017 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2015-05-28 Health Canada: Marketed since 2020-08-05 · brand TARO-CYPROTERONE/ETHINYL ESTRADIOL · ATC G03HB01 CYPROTERONE AND ESTROGEN · form Tablet · route Oral · ingredients CYPROTERONE ACETATE 2 MG, ETHINYL ESTRADIOL 0.035 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90968 · Verify on the e-Formulary ↗ (DIN 02425017)

Source record
DIN 02425017: Ran-Cyproterone/Ethinyl Estradiol Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 683200100; group id 792; item number 1929; lccId None; manufacturer id RAN Source form: Tab-21 Pk; strength: 2mg & 0.035mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $23.3394; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02425017 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90968
Interchangeable products
AMB-Cyproterone Acetate/EthinylEstradiol · DIN 02564424 · not recorded Cleo-35 · DIN 02436736 · not recorded Cyestra-35 · DIN 02290308 · not recorded Diane-35 · DIN 02233542 · not recorded Teva-Cyproterone/Ethinyl Estradiol · DIN 02309556 · not recorded
Shortage status: resolved shortage (ended 2026-08-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02425017
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Cyproterone/Ethinyl Estradiol · DIN 02309556 · 2mg & 0.035mg · tablets, 21-pack

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Cyproterone/Ethinyl Estradiol · DIN 02309556 Manufacturer: Teva Canada Limited; listing date 2008-12-03 Health Canada: Marketed since 2018-03-08 · brand TEVA-CYPROTERONE / ETHINYL ESTRADIOL · ATC G03HB01 CYPROTERONE AND ESTROGEN · form Tablet · route Oral · ingredients CYPROTERONE ACETATE 2 MG, ETHINYL ESTRADIOL 0.035 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79517 · Verify on the e-Formulary ↗ (DIN 02309556)

Source record
DIN 02309556: Teva-Cyproterone/Ethinyl Estradiol Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 683200100; group id 792; item number 1929; lccId None; manufacturer id TEV Source form: Tab-21 Pk; strength: 2mg & 0.035mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $23.3400; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02309556 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79517
Interchangeable products
AMB-Cyproterone Acetate/EthinylEstradiol · DIN 02564424 · not recorded Cleo-35 · DIN 02436736 · not recorded Cyestra-35 · DIN 02290308 · not recorded Diane-35 · DIN 02233542 · not recorded Ran-Cyproterone/Ethinyl Estradiol · DIN 02425017 · not recorded
Shortage status: resolved shortage (ended 2023-06-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02309556
Shortage record checked 2026-09-13T08:10:21.292534+00:00

DESOGESTREL & ETHINYL ESTRADIOL

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (G03CA) — coverage varies; not interchangeable

  • Conjugated estrogens (Premarin): general benefit, Limited Use 398

Apri 21 · DIN 02317192 · 0.15mg & 0.03mg · tablets, 21-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apri 21 · DIN 02317192 Manufacturer: Barr Laboratories Inc.; listing date 2009-04-01 Health Canada: Marketed since 2015-05-28 · brand APRI 21 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.15 MG, ETHINYL ESTRADIOL 0.03 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Apri 21: Formulary list price $5.2773/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2773 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80270 · Verify on the e-Formulary ↗ (DIN 02317192)

Source record
DIN 02317192: Apri 21 Raw flags: sec3=Y Item: 683200094; group id 793; item number 1930; lccId None; manufacturer id BAR Source form: Tab-21 Pk; strength: 0.15mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $5.2773; ministry $5.2773 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02317192 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80270
Interchangeable products
Freya 21 · DIN 02396491 · $5.2773 Marvelon 21 · DIN 02042487 · $5.2773 Miley 21 · DIN 02556553 · $5.2773 Mirvala 21 · DIN 02410249 · $5.2773
Shortage status: resolved shortage (ended 2022-12-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02317192
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Freya 21 · DIN 02396491 · 0.15mg & 0.03mg · tablets, 21-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Freya 21 · DIN 02396491 Manufacturer: Famy Care Ltd; listing date 2013-05-31 Health Canada: Marketed since 2016-09-19 · brand FREYA 21 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.03 MG, DESOGESTREL 0.15 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Freya 21: Formulary list price $5.2773/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2773 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88154 · Verify on the e-Formulary ↗ (DIN 02396491)

Source record
DIN 02396491: Freya 21 Raw flags: sec3=Y Item: 683200094; group id 793; item number 1930; lccId None; manufacturer id FAM Source form: Tab-21 Pk; strength: 0.15mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $5.2773; ministry $5.2773 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02396491 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88154
Interchangeable products
Apri 21 · DIN 02317192 · $5.2773 Marvelon 21 · DIN 02042487 · $5.2773 Miley 21 · DIN 02556553 · $5.2773 Mirvala 21 · DIN 02410249 · $5.2773
Shortage status: resolved shortage (ended 2022-10-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02396491
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Marvelon 21 · DIN 02042487 · 0.15mg & 0.03mg · tablets, 21-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Marvelon (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Marvelon 21 · DIN 02042487 Manufacturer: Organon Canada Ltd./Ltee; listing date 1996-10-01 Health Canada: Marketed since 2022-05-19 · brand MARVELON 21 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.03 MG, DESOGESTREL 0.15 MG · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.2773 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14354 · Verify on the e-Formulary ↗ (DIN 02042487)

Source record
DIN 02042487: Marvelon 21 Raw flags: sec3=Y Item: 683200094; group id 793; item number 1930; lccId None; manufacturer id ORG Source form: Tab-21 Pk; strength: 0.15mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $22.1600; ministry $5.2773 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02042487 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14354
Interchangeable products
Apri 21 · DIN 02317192 · $5.2773 Freya 21 · DIN 02396491 · $5.2773 Miley 21 · DIN 02556553 · $5.2773 Mirvala 21 · DIN 02410249 · $5.2773
Shortage status: resolved shortage (ended 2018-02-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02042487
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Miley 21 · DIN 02556553 · 0.15mg & 0.03mg · tablets, 21-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Miley 21 · DIN 02556553 Manufacturer: Ambicare Pharmaceuticals Inc.; listing date 2025-10-31 Health Canada: Marketed since 2025-08-18 · brand MILEY 21 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.03 MG, DESOGESTREL 0.15 MG · company Ambicare pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

Miley 21: Formulary list price $5.2773/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2773 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104524 · Verify on the e-Formulary ↗ (DIN 02556553)

Source record
DIN 02556553: Miley 21 Raw flags: sec3=Y Item: 683200094; group id 793; item number 1930; lccId None; manufacturer id AMB Source form: Tab-21 Pk; strength: 0.15mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $5.2773; ministry $5.2773 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02556553 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104524
Interchangeable products
Apri 21 · DIN 02317192 · $5.2773 Freya 21 · DIN 02396491 · $5.2773 Marvelon 21 · DIN 02042487 · $5.2773 Mirvala 21 · DIN 02410249 · $5.2773
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02556553
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mirvala 21 · DIN 02410249 · 0.15mg & 0.03mg · tablets, 21-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mirvala 21 · DIN 02410249 Manufacturer: Apotex Inc.; listing date 2014-01-30 Health Canada: Marketed since 2014-01-07 · brand MIRVALA 21 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.1500 MG/TAB, ETHINYL ESTRADIOL 0.0300 MG/TAB · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Mirvala 21: Formulary list price $5.2773/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2773 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89490 · Verify on the e-Formulary ↗ (DIN 02410249)

Source record
DIN 02410249: Mirvala 21 Raw flags: sec3=Y Item: 683200094; group id 793; item number 1930; lccId None; manufacturer id APX Source form: Tab-21 Pk; strength: 0.15mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $5.2773; ministry $5.2773 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02410249 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89490
Interchangeable products
Apri 21 · DIN 02317192 · $5.2773 Freya 21 · DIN 02396491 · $5.2773 Marvelon 21 · DIN 02042487 · $5.2773 Miley 21 · DIN 02556553 · $5.2773
Shortage status: resolved shortage (ended 2026-04-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02410249
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apri 28 · DIN 02317206 · 0.15mg & 0.03mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apri 28 · DIN 02317206 Manufacturer: Barr Laboratories Inc.; listing date 2009-04-01 Health Canada: Marketed since 2015-05-28 · brand APRI 28 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.03 MG, DESOGESTREL 0.15 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Apri 28: Formulary list price $5.2780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80272 · Verify on the e-Formulary ↗ (DIN 02317206)

Source record
DIN 02317206: Apri 28 Raw flags: sec3=Y Item: 683200093; group id 793; item number 1931; lccId None; manufacturer id BAR Source form: Tab-28 Pk; strength: 0.15mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $5.2780; ministry $5.2780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02317206 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80272
Interchangeable products
Freya 28 · DIN 02396610 · $5.2780 Marvelon 28 · DIN 02042479 · $5.2780 Miley 28 · DIN 02556561 · $5.2780 Mirvala 28 · DIN 02410257 · $5.2780
Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02317206
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Freya 28 · DIN 02396610 · 0.15mg & 0.03mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Freya 28 · DIN 02396610 Manufacturer: Famy Care Ltd; listing date 2013-05-31 Health Canada: Marketed since 2016-09-19 · brand FREYA 28 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.03 MG, DESOGESTREL 0.15 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Freya 28: Formulary list price $5.2780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88165 · Verify on the e-Formulary ↗ (DIN 02396610)

Source record
DIN 02396610: Freya 28 Raw flags: sec3=Y Item: 683200093; group id 793; item number 1931; lccId None; manufacturer id FAM Source form: Tab-28 Pk; strength: 0.15mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $5.2780; ministry $5.2780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02396610 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88165
Interchangeable products
Apri 28 · DIN 02317206 · $5.2780 Marvelon 28 · DIN 02042479 · $5.2780 Miley 28 · DIN 02556561 · $5.2780 Mirvala 28 · DIN 02410257 · $5.2780
Shortage status: resolved shortage (ended 2022-10-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02396610
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Marvelon 28 · DIN 02042479 · 0.15mg & 0.03mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Marvelon (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Marvelon 28 · DIN 02042479 Manufacturer: Organon Canada Ltd./Ltee; listing date 1996-10-01 Health Canada: Marketed since 2022-06-17 · brand MARVELON 28 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.15 MG, ETHINYL ESTRADIOL 0.03 MG · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.2780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14355 · Verify on the e-Formulary ↗ (DIN 02042479)

Source record
DIN 02042479: Marvelon 28 Raw flags: sec3=Y Item: 683200093; group id 793; item number 1931; lccId None; manufacturer id ORG Source form: Tab-28 Pk; strength: 0.15mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $22.1600; ministry $5.2780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02042479 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14355
Interchangeable products
Apri 28 · DIN 02317206 · $5.2780 Freya 28 · DIN 02396610 · $5.2780 Miley 28 · DIN 02556561 · $5.2780 Mirvala 28 · DIN 02410257 · $5.2780
Shortage status: resolved shortage (ended 2021-06-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02042479
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Miley 28 · DIN 02556561 · 0.15mg & 0.03mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Miley 28 · DIN 02556561 Manufacturer: Ambicare Pharmaceuticals Inc.; listing date 2025-10-31 Health Canada: Marketed since 2025-08-18 · brand MILEY 28 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.03 MG, DESOGESTREL 0.15 MG · company Ambicare pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

Miley 28: Formulary list price $5.2780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104525 · Verify on the e-Formulary ↗ (DIN 02556561)

Source record
DIN 02556561: Miley 28 Raw flags: sec3=Y Item: 683200093; group id 793; item number 1931; lccId None; manufacturer id AMB Source form: Tab-28 Pk; strength: 0.15mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $5.2780; ministry $5.2780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02556561 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104525
Interchangeable products
Apri 28 · DIN 02317206 · $5.2780 Freya 28 · DIN 02396610 · $5.2780 Marvelon 28 · DIN 02042479 · $5.2780 Mirvala 28 · DIN 02410257 · $5.2780
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02556561
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (68:00 HORMONES AND SUBSTITUTES) and how they are covered

Matched class: 68:00 HORMONES AND SUBSTITUTES

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CANAGLIFLOZIN, CICLESONIDE, DANAZOL, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, DROSPIRENONE, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, ETONOGESTREL, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC (RDNA ORIGIN), INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN), INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%, INSULIN DEGLUDEC, INSULIN DETEMIR, INSULIN GLARGINE & LIXISENATIDE, INSULIN GLULISINE (DNA ORIGIN), INSULIN HUMAN BIOSYNTHETIC, INSULIN HUMAN BIOSYNTHETIC 30% & ISOPHANE 70%, INSULIN INJECTION, HUMAN BIOSYNTHETIC, INSULIN LISPRO & INSULIN LISPRO PROTAMINE, LEVONORGESTREL, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, PROPYLTHIOURACIL, RELUGOLIX, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN, THYROTROPIN ALFA, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, CALCITONIN (SALMON SYNTHETIC), CONJUGATED ESTROGENS, DESMOPRESSIN ACETATE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, GLICLAZIDE, GLYBURIDE, HYDROCORTISONE, INSULIN ASPART, INSULIN GLARGINE, INSULIN LISPRO, LEVOTHYROXINE (SODIUM), MEDROXYPROGESTERONE ACETATE, METFORMIN HCL, METHIMAZOLE, NORETHINDRONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:00 HORMONES AND SUBSTITUTES

RELUGOLIX

· 1 products · General benefit · strengths: 120mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:00 68:04 Corticosteroids

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 65 more
Full class listing Related classes:

Other drugs in the same formulary class (68:12 Contraceptives) and how they are covered

Matched class: 68:12 Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ETONOGESTREL, LEVONORGESTREL 68:12 Contraceptives

ETONOGESTREL

· 1 products · General benefit · strengths: 68mg/Implant · ER Subdermal Implant

LEVONORGESTREL

· 2 products · General benefit · strengths: 19.5mg, 52mg · Insert Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:12
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids

Other drugs in the same formulary class (68:16 Estrogens) and how they are covered

Matched class: 68:16 Estrogens

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CONJUGATED ESTROGENS 68:16 Estrogens

CONJUGATED ESTROGENS

· 2 products · Limited Use, codes 398 (1), General benefit (1) · strengths: 0.625mg, 0.625mg/g · SR Tab, Vag Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:16
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids

Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DROSPIRENONE, LEVONORGESTREL Some products covered without a code (check the product listing): MEDROXYPROGESTERONE ACETATE, NORETHINDRONE 68:32 Progestogens and Oral Contraceptives

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

MEDROXYPROGESTERONE ACETATE

· 10 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (4), Listed, not a benefit (1) · strengths: 150mg/mL, 2.5mg, 5mg, 10mg, 100mg · Inj Sol-1mL Pref Syr, Tab

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: conception control
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. NORETHINDRONE · Listed, not a benefit (1), General benefit (2) INDICATIONS AND CLINICAL USE MOVISSE Tablets are indicated for conception control. PM: https://pdf.hres.ca/dpd_pm/00085300.PDF; date JUL 10, 2026; DIN 02410303; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications ESTRING (17 β-estradiol) is indicated for postmenopausal urogenital complaints due to estrogen deficiency such as feeling of dryness in the vagina (atrophic vaginitis) with or without pruritus vulvae, dyspareunia, dysuria and urinary urgency (atrophic mucosa in the urethra and trigonum). ESTRING should be prescribed with an appropriate dosage of a progestin for women with intact uteri, in order to prevent endometrial hyperplasia/carcinoma. The maximum recommended duration of continuous therapy is 2 years. 1.1. Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (> 65 years of age): There have not been sufficient numbers of geriatric patients involved in studies utilizing ESTRING to determine whether those over 65 years of age differ from younger subjects in their response to ESTRING (See 7 Warnings and Precautions: Special Populations: Geriatrics). https://pdf.hres.ca/dpd_pm/00083118.PDF PM date: 2026-01-08 Source product: ESTRING; DIN 02168898; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS IMVEXXY ® (17 β-estradiol) is indicated for: • the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy. IMVEXXY clinical effectiveness is supported by safety and efficacy data based on a 12-week study. The safety and efficacy of longer-term use of IMVEXXY have not been established (see 14 CLINICAL TRIALS). 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): There have not been sufficient numbers of geriatric women involved in clinical studies utilizing IMVEXXY to determine whether those over 65 years of age differ from younger subjects in their response to IMVEXXY. https://pdf.hres.ca/dpd_pm/00077738.PDF PM date: AUG 13, 2020 Source product: IMVEXXY; DIN 02503689; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE DIANE-35 (cyproterone acetate and ethinyl estradiol) is indicated for:  treatment of women with severe acne, with associated symptoms of androgenization, including seborrhea and mild hirsutism. DIANE-35 should be used only when acne is unresponsive to topical therapy and oral antibiotic treatments. Note: DIANE-35 should not be prescribed for the purpose of contraception alone. However, when taken as recommended (see DOSAGE AND ADMINISTRATION), DIANE-35 will provide reliable contraception in patients treated for the above clinical conditions. If patient compliance is uncertain and contraception is necessary, then a supplementary non-hormonal contraceptive method should be considered. Geriatrics DIANE-35 is not indicated after menopause. Pediatrics DIANE-35 is only indicated after menarche. https://pdf.hres.ca/dpd_pm/00038573.PDF PM date: March 16, 2017 Source product: DIANE-35; DIN 02233542; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS MARVELON® (desogestrel/ethinyl estradiol tablets, USP) is indicated for: • Conception control 1.1 Pediatrics Pediatrics: The safety and efficacy of MARVELON® has not been established in women under the age of 18 years. Use of this product before menarche is not indicated. 1.2 Geriatrics Geriatrics: MARVELON® is not indicated in postmenopausal women. https://pdf.hres.ca/dpd_pm/00077799.PDF PM date: NOV 20, 2024 Source product: MARVELON 28; DIN 02042479; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications YASMIN (drospirenone and ethinyl estradiol tablet) is indicated for: • Conception Control • Treatment of moderate acne vulgaris in women ≥16 years of age who have no known contraindications to oral contraceptive therapy, desire contraception, and have achieved menarche 1.1 Pediatrics Pediatrics (˂16 years of age): The safety and efficacy of YASMIN has not been established in women under the age of 16 years. Use of this product before menarche is not indicated (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics: YASMIN is not indicated for use in postmenopausal women. No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00080997.PDF PM date: 2025-07-07 Source product: YASMIN 21; DIN 02261723; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS Vagifem® 10 (estradiol vaginal insert USP) is indicated for: • The treatment of the symptoms of vaginal atrophy due to estrogen deficiency 1.1 Pediatrics Pediatrics (<18 years of age): Vagifem® 10 is not indicated for use in the pediatric population. https://pdf.hres.ca/dpd_pm/00073342.PDF PM date: not printed or not captured Source product: VAGIFEM 10; DIN 02325462; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS BIJUVA (estradiol and progesterone capsule) is indicated for: • Treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus. BIJUVA is recommended for use only in patients with an intact uterus since the regimen includes a progestogen whose role is to assist in the prevention of endometrial hyperplasia. 1.1 Pediatrics Pediatrics (<18 years of age): BIJUVA is not indicated for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): BIJUVA has not been studied in women over 65 years old; therefore, BIJUVA is not recommended in women over 65 years of age. https://pdf.hres.ca/dpd_pm/00077597.PDF PM date: SEP 16, 2020 Source product: BIJUVA; DIN 02505223; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS NUVARING® (etonogestrel/ethinyl estradiol slow release vaginal ring) is indicated for: • Conception control 1.1 Pediatrics Pediatrics (˂18 years of age): The safety and efficacy of NUVARING in adolescents under the age of 18 have not been studied. Use of this product before menarche is not indicated. 1.2 Geriatrics Geriatrics: NUVARING has not been studied in postmenopausal women and is not indicated in this population. https://pdf.hres.ca/dpd_pm/00077755.PDF PM date: DEC 12, 2004 Source product: NUVARING; DIN 02253186; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications TRIQUILAR (levonorgestrel and ethinyl estradiol) is indicated for: • Conception control 1.1 Pediatrics Pediatrics (˂16 years of age): Based on the data submitted and reviewed by Health Canada, Health Canada has authorized an indication in women of reproductive age. TRIQUILAR is not indicated for use before menarche (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics: TRIQUILAR is not indicated for use in postmenopausal women. No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00081001.PDF PM date: 2025-07-07 Source product: TRIQUILAR 28; DIN 00707503; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications BREVICON 0.5/35 and BREVICON 1/35 (norethindrone and ethinyl estradiol) are indicated for: • the prevention of pregnancy. 1.1. Pediatrics The safety and efficacy of BREVICON has been established in women of reproductive age. Use of these products before menarche is not indicated. 1.2. Geriatrics BREVICON is not indicated for use in postmenopausal women. https://pdf.hres.ca/dpd_pm/00081309.PDF PM date: 2025-08-07 Source product: BREVICON 0.5/35 TABLETS (21-DAY PACK); DIN 02187086; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
1 INDICATIONS LOLO® (ethinyl estradiol / norethindrone acetate and ethinyl estradiol) is indicated for: • the prevention of pregnancy. In a one year (thirteen 28-day cycles) multicenter open-label clinical trial 1,582 women were studied to assess the safety and efficacy of LOLO. In this study 1,270 women 18 to 35 years of age were studied to assess the efficacy of LOLO, completing the equivalent of 12,482 28-day evaluable cycles of exposure. The pregnancy rate (Pearl Index [PI]) in women 18 to 35 years of age was 2.92 pregnancies per 100 women-years of use. See 14 CLINICAL TRIALS. The efficacy of LOLO in women with a body mass index > 35 kg/m2 has not been evaluated. Exposure to exogenous estrogen with LOLO is less than with other combined oral contraceptives with similar synthetic estrogens. Any benefits from the lower estrogen exposure provided by LOLO have not been evaluated. 1.1 Pediatrics Pediatrics (< 18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for… https://pdf.hres.ca/dpd_pm/00077458.PDF PM date: DEC 12, 2013 Source product: LOLO; DIN 02417456; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications TRI-CIRA LOTM 21 and TRI-CIRA LOTM 28 (Norgestimate and Ethinyl Estradiol Tablets) are indicated for:  Conception control. 1.1. Pediatrics Pediatrics (< 16 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of TRI-CIRA LOTM 21 and TRI-CIRA LOTM 28 in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. See 7.1.3 Pediatrics. 1.2. Geriatrics Geriatrics (> 65 years of age): TRI-CIRA LOTM 21 and TRI-CIRA LOTM 28 are not indicated for use in post- menopausal women. See 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00081457.PDF PM date: 2025-08-21 Source product: TRI-CIRA LO 21; DIN 02401967; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS MYFEMBREE (relugolix, estradiol, and norethindrone acetate tablets) is indicated in premenopausal women for the management of heavy menstrual bleeding associated with uterine fibroids and for the management of moderate to severe pain associated with endometriosis. 1.1 Pediatrics Pediatrics (<18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: MYFEMBREE is not indicated in postmenopausal women and has not been studied in women over 50 years of age. https://pdf.hres.ca/dpd_pm/00082196.PDF PM date: OCT 13, 2023 Source product: MYFEMBREE; DIN 02541742; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Estrace · DIN 02225190 Shortage status: active shortage (reported 2019-07-01, last updated 2021-10-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02225190

Check this DIN again

Estrace · DIN 02148587 Shortage status: active shortage (reported 2019-07-01, last updated 2021-10-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02148587

Check this DIN again

Estrace · DIN 02148595 Shortage status: active shortage (reported 2019-07-01, last updated 2021-10-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02148595

Check this DIN again

Apri 28 · DIN 02317206 Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02317206

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Estrace, AMB-Cyproterone Acetate/EthinylEstradiol, Cleo-35, Cyestra-35, Diane-35, Ran-Cyproterone/Ethinyl Estradiol, Teva-Cyproterone/Ethinyl Estradiol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026